Orchid Pharma has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (USFDA) for Aripiprazole tablets USP, 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg on May 24, 2017. Aripiprazole tablets are atypical antipsychotic indicated in the treatment symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression).
Orchid Pharma is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs.
